See the DrugPatentWatch profile for entresto
Is there a generic version of Entresto available in Europe?
Entresto is a prescription heart-failure medicine containing the combination sacubitril/valsartan. As of the information provided here, there isn’t enough detail to confirm whether any generic (or authorized generic) versions are currently marketed across European countries, since availability depends on patent status, regulatory approval by the EMA (for EU-wide access), and national launches.
When could generic Entresto launch in Europe?
In Europe, the timing for generic entry typically depends on:
- Patent and supplementary protection certificate (SPC) expiry dates for sacubitril/valsartan combinations.
- Any court rulings or settlements that affect market entry.
- Regulatory approval status under EU medicines rules (EMA evaluation for central authorization, then local marketing).
If you share which EU country you care about (for example, UK, Germany, France, Italy, Spain, or Poland), I can narrow the answer to the most relevant market and pathway.
What counts as a “generic” for Entresto in practice?
People may mean different things when they say “generic Entresto”:
- A true generic (same active ingredients, same strength, and bioequivalent).
- An “authorized” generic sold by a different company under an authorization arrangement.
- A comparable product approved as a biosimilar-like concept does not apply here; Entresto is a small-molecule fixed-dose combination, so the relevant concept is generic/bioequivalent, not biosimilar substitution.
Can pharmacies substitute Entresto with a cheaper equivalent in Europe?
Substitution rules differ by country. Even if a product is approved, automatic substitution is not always allowed everywhere, and switching may be restricted for narrow safety/efficacy reasons or by prescriber instruction. National regulations and the specific reimbursement rules determine whether a lower-cost product is actually dispensed instead of Entresto.
Which European regulatory routes decide approval for generics?
A generic intended for EU-wide availability is typically approved through the EU regulatory framework (often via the central EMA process for certain products, or via national routes where applicable). The key point for consumers is that approval does not equal immediate availability at retail level; launch and reimbursement can lag.
What could block generic Entresto entry even if patents expire?
Even after key IP terms end, market entry can still be delayed by:
- Ongoing litigation involving formulation, process, or method-of-use patents.
- Regulatory exclusivities or additional protective filings (depending on the case).
- Local reimbursement negotiations and supply readiness.
How to check whether a generic exists in your country right now
If you tell me your country, I can guide you on the most reliable checks, such as:
- National medicine registries and official product databases.
- Pharmacy listings for sacubitril/valsartan branded vs generic names.
- Whether prescriptions are written as “Entresto” (brand) versus “sacubitril/valsartan” (generic by substance).
If you reply with the country (and dose, if you want), I’ll tailor the answer to what’s likely available there and what to look for on the box and prescription.
Sources
No sources were provided in your prompt, so I did not cite any.